|
The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment |
May 2025 |
Turkish Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Where There's Smoke, There's Fire: Inflammation Drives MDS |
Jul 2020 |
Trends in immunology |
Myelodysplastic Syndromes (MDS) |
|
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy |
Sep 2024 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
|
Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia |
Apr 2021 |
Transplantation and Cellular Therapy |
Aplastic Anemia, Graft Versus Host Disease (GVHD) |
|
Excellent Outcomes in Feasibility Study of Radiation-Free Conditioning and Transplant in Pediatric Severe Aplastic Anemia. |
Sep 2025 |
Transplantation and Cellular Therapy |
Aplastic Anemia |
|
Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
Apr 2023 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
|
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
Jul 2023 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
|
Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators |
Dec 2024 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms |
Jul 2024 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
|
Management of myelodysplastic syndromes after failure of response to hypomethylating agents |
May 2019 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
